Business · 29/04/2022Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Gilead Sciences for VEKLURY (Remdesivir) Material Threat Medical Countermeasure Product
Summary
The FDA has issued a priority review voucher to Gilead Sciences, the manufacturer of VEKLURY (remdesivir), a material threat medical countermeasure product, following a review of its application under the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →